JAKARTA, AYOBANDUNG.COM – Coordinating Minister for the Economy, Airlangga Hartarto said, 30 million doses vaccine Corona Sinovac was accepted by Indonesia in the fourth quarter of this year. If the clinical trials currently underway are successful, vaccinations are expected to start in the first quarter of 2021.
Airlangga explained that Indonesia had access vaccine Sinovac as much as 250 million to 300 million doses. However, this year, the government has only received a commitment of 30 million doses.
“Later, in the first quarter of 2021, we will be able to vaccinate the subject to the success of clinical trials,” he said in a virtual workshop of 100 Economists, Tuesday (15/9).
The government, through the holding company of the state-owned pharmaceutical company Bio Farma, is ready to conduct clinical trials for phase three vaccine Sinovac. As an initial stage of the third stage clinical trial, vaccine has arrived at Bio Farma on July 19, 2020 as many as 2,400 vaccine to be tested in August.
Apart from Sinovac, explained, the government also hooked up other private companies in development vaccine Covid-19. Among them are the Wuhan Institute Biological Products, which is also partnered with Sinopharm. For partners in Indonesia, the development will be carried out together with PT Kimia Farma.
According to the presentation delivered by Airlangga, the third phase of clinical trials is currently underway in the United Arab Emirates (UAE) vaccine the.
Resources for development vaccine Next up is Astra Zeneca, which is currently undergoing a third phase of clinical trials in the UK, America, Brazil and South Africa.
The government also hooked up the Global Alliance for Vaccines and Immunization (GAVI) and the Coalition for Epidemic Preparedness Innovations (CEPI) to develop vaccine Covid-19 in Indonesia.
Through GAVI and CEPI, Airlangga said that the Indonesian government could get it vaccine at a lower price. “It can be up to three to five US dollars, while the Sinovac is between 10 and 20 US dollars,” he said.
The government through the Ministry of Research, Technology and Higher Education (Kemenristekdikti) is now also preparing vaccine Red and white. In the accelerated formulation process, it is hoped that the third clinical trial can be completed by the end of 2021.
Previously, Airlangga said the government had budgeted Rp. 3.3 trillion for down payments (DP) in procurement vaccine. These funds are already available and entered in the 2020 fiscal year.
The amount of DP is around 10 percent of the total budget prepared by the government for procurement vaccine. “The entire fund prepared is Rp. 37 trillion for the multi-year program,” said Airlangga at the Handling Committee Press Conference Covid-19 and National Economic Recovery (PC-PEN), Friday (4/9).
–
This news is the result of a collaboration between Ayo Media Network and Republika.co.id.
The content of the writing is outside the responsibility of Ayo Media Network.
– .
